These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37014530)

  • 1. Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey.
    Zurowska A; Drozynska-Duklas M; Topaloglu R; Bouts A; Boyer O; Shenoy M; Vivarelli M;
    Pediatr Nephrol; 2023 Sep; 38(9):3035-3042. PubMed ID: 37014530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.
    Parmentier C; Delbet JD; Decramer S; Boyer O; Hogan J; Ulinski T
    Pediatr Nephrol; 2020 Mar; 35(3):455-462. PubMed ID: 31705306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?
    Delbe-Bertin L; Aoun B; Tudorache E; Lapillone H; Ulinski T
    Pediatr Nephrol; 2013 Mar; 28(3):447-51. PubMed ID: 23212560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome.
    Inoki Y; Kamei K; Nishi K; Sato M; Ogura M; Ishiguro A
    Pediatr Nephrol; 2022 May; 37(5):1057-1066. PubMed ID: 34606002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome.
    Fujinaga S; Ozawa K; Sakuraya K; Yamada A; Shimizu T
    Clin Nephrol; 2016 Jun; 85(6):340-5. PubMed ID: 27125626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
    Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
    Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai.
    Sun L; Xu H; Shen Q; Cao Q; Rao J; Liu HM; Fang XY; Zhou LJ
    World J Pediatr; 2014 Feb; 10(1):59-63. PubMed ID: 24464665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single Dose of Rituximab in Children with Steroid-Dependent / Frequently Relapsing Nephrotic Syndrome, Clinical Efficacy and Evaluation of Health-Related Quality of Life.
    Wang L; Hua R; Zhu Y; Lu Y; Gao H; Xia X; Zhang Q; Lu L; Deng F
    Iran J Kidney Dis; 2021 Mar; 1(2):109-115. PubMed ID: 33764321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects.
    Sinha A; Mathew G; Arushi A; Govindarajan S; Ghanapriya K; Grewal N; Rai K; Brijwal M; Kalluru SL; Tewari P; Misra A; Khandelwal P; Hari P; Bagga A
    Nephrol Dial Transplant; 2023 Mar; 38(4):939-949. PubMed ID: 36071552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
    Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for nephrotic syndrome in children.
    Iijima K; Sako M; Nozu K
    Clin Exp Nephrol; 2017 Apr; 21(2):193-202. PubMed ID: 27422620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
    Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
    Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
    Chan EY; Yu ELM; Angeletti A; Arslan Z; Basu B; Boyer O; Chan CY; Colucci M; Dorval G; Dossier C; Drovandi S; Ghiggeri GM; Gipson DS; Hamada R; Hogan J; Ishikura K; Kamei K; Kemper MJ; Ma AL; Parekh RS; Radhakrishnan S; Saini P; Shen Q; Sinha R; Subun C; Teo S; Vivarelli M; Webb H; Xu H; Yap HK; Tullus K
    J Am Soc Nephrol; 2022 Jun; 33(6):1193-1207. PubMed ID: 35354600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.
    Fujinaga S; Nishino T; Umeda C; Tomii Y; Watanabe Y; Sakuraya K
    Pediatr Nephrol; 2019 Feb; 34(2):353-357. PubMed ID: 30426219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
    Ito S; Kamei K; Ogura M; Sato M; Fujimaru T; Ishikawa T; Udagawa T; Iijima K
    Pediatr Nephrol; 2011 Oct; 26(10):1823-8. PubMed ID: 21556716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
    BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience.
    Evangelatos G; Fragoulis GE; Klavdianou K; Moschopoulou M; Vassilopoulos D; Iliopoulos A
    Rheumatology (Oxford); 2021 May; 60(5):2375-2382. PubMed ID: 33175958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.
    Van Horebeek I; Knops N; Van Dyck M; Levtchenko E; Mekahli D
    Acta Clin Belg; 2017 Jun; 72(3):147-155. PubMed ID: 27409338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of low-dose rituximab in treatment of pediatric nephrotic syndrome: a prospective randomized controlled trial].
    Zhu Y; Wu L; Wang Y; Zhu YF; Peng Y; Fang SH; Zhang LD; Deng F
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jun; 25(6):606-611. PubMed ID: 37382130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.